Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.31 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048489 | 0.83 | POLB (0.43) | HPGDALDH1A1MAPTGAAAGTR1 | |
| SCHEMBL7051028 | 0.82 | POLB (0.42) | HPGDGAAAGTR1AGTR2KMT2A | |
| SCHEMBL7049851 | 0.82 | AKR1C2 (0.38) | HPGDALDH1A1MAPTGAA | |
| SCHEMBL7052349 | 0.80 | MAPT (0.35) | HPGDALDH1A1MAPTGAAAGTR1 | |
| SCHEMBL7052307 | 0.79 | ALDH1A1 (0.33) | HPGDALDH1A1MAPTAGTR1AGTR2 | |
| SCHEMBL7050679 | 0.77 | ALDH1A1 (0.32) | HPGDALDH1A1MAPTAGTR1AGTR2 | |
| SCHEMBL7076349 | 0.73 | BCL2L1 (0.43) | — | |
| SCHEMBL7076569 | 0.71 | SMPD1 (0.53) | — | |
| SCHEMBL7049821 | 0.70 | HDAC1 (0.34) | — | |
| SCHEMBL7049828 | 0.67 | PTGES (0.49) | ALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191323-A1 | Hypoglycemic agent | AJINOMOTO CO., INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1300142-A1 | HYPOGLYCEMICS | Ajinomoto Co., Inc. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | HPGD 3434/4885ALDH1A1 385/4885MAPT 3922/4885 |
| US-20030191323-A1 | Hypoglycemic agent | GPR119, IAPP, SLC5A2 | HPGD 1451/4885ALDH1A1 410/4885MAPT 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.